Royalty Report: Drugs, Cancer, Disease – Collection: 30031

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Pharmaceuticals
  • Therapeutic
  • Antibody
  • Immune
  • Vaccine
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 30031

License Grant
The company granted an exclusive development and commercialization license to use maytansinoid ADC (antibody-drug conjugates) technology with antibodies, such as trastuzumab, or other proteins that target HER2.
License Property
Kadcyla is a HER2-targeting ADC that consists of trastuzumab antibody with our DM1 cell-killing agent attached using one of our engineered linkers.
Field of Use
In February 2013, the U.S. FDA granted marketing approval to the HER2-targeting ADC compound, Kadcyla.

KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including a taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery.

IPSCIO Record ID: 1346

License Grant
The agreement is based on worldwide sales of trastuzumab emtansine (T-DM1) by the Licensee and its subLicensees.
License Property
Trastuzumab emtansine is an antibody-drug conjugate consisting of the monoclonal antibody trastuzumab (Herceptin) linked to the cytotoxic agent mertansine (DM1). Its main use is to treat certain breast cancers.

IPSCIO Record ID: 306612

License Grant
Licensor, a nonprofit organization providing investigators and clinicians scientific, granted exclusive worldwide rights to several U.S. and foreign patents and patent applications.
License Property
The patents and patent applications covering methods of using GP2 as an immunotherapy that elicits a targeted immune response against HER2/neu-expressing cancers.

GP2 is an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The patents are titled Vaccine for the Prevention of Breast Cancer Recurrence, and, Targeted Identification of Immunogenic Peptides.

GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. In a Phase IIb clinical trial completed in 2018, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months.

Following breast cancer surgery, a HER2/neu 3+ patient receives Herceptin in the first year, with the hope that their breast cancer will not recur, with the odds of recurrence slowly decreasing over the first 5 years after surgery. Herceptin has been shown to reduce recurrence rates from 25% to 12% in the adjuvant setting while Kadcyla has been shown to reduce recurrence rates from 22% to 11% in the neoadjuvant setting.

Patent 1 –
Title Vaccine for the Prevention of Breast Cancer Recurrence
Provisional Patent Application No. 61/121,220

Patent 2 –
Title Targeted Identification of Immunogenic Peptides
as described in U.S. Patent Application No. 12/045,402 filed on 3/10/2008 and Australian Application No. 2008201427 filed on 3/28/2008, both claiming priority to U.S. Provisional Application No. 60/714,865 filed on 09/08/2005 and International Application No. PCT/US2006/035171 filed on 09/08/2006; and
as described in International Application No. PCT/US2006/035171 filed on 09/08/2006 and all corresponding National Stage Applications including but not limited to Japanese Patent Application No. 2008-530244, European Patent Application No. 06824918.4 filed on 3/31/2008, and Canadian Patent Application No. 2,622,036 filed on 3/10/2008; and
as described in International Application No. PCT/GB2008/050227 filed 03/28/2008 and all its corresponding National Stage Applications

Field of Use
The field of use is to develop and advance GP2 immunotherapy towards commercialization.

The Field means (a) all fields of use with respect to Patent titled Vaccine for the Prevention of Breast Cancer Recurrence; and (b) use of the HER family peptide GP2 in combination with Herceptin® and only in the field of human therapeutics with respect to Patent titled Targeted Identification of Immunogenic Peptides.

This agreement is in support of the GP2 breast cancer vaccine Phase II clinical trial.

Licensee believes that GP2 may be used to address the 50% of recurring cancer patients who do not respond to either Herceptin or Kadcyla in the treatment of breast cancer.

IPSCIO Record ID: 240612

License Grant
This amendment details terms, clarifies transfers of technology and modifies the royalty.  The original agreement is exclusive.
License Property
The licensed property is regarding Licensors antibody-drug conjugate technology.

'ADCs utilize the targeting ability of monoclonal antibodies to deliver potent, cell-killing payloads to specific cells.  ADC technology employs synthetic, highly potent drugs that can be attached to antibodies through proprietary linker systems. The linkers are designed to be stable in the bloodstream but to release the drug payload under specific conditions once inside target cells, thereby sparing non-target cells many of the toxic effects of traditional chemotherapy.

Field of Use
The Field, described in the original agreement, means any and all Antibody targeting applications for human or animal use unless mutually agreed to by the Parties.

IPSCIO Record ID: 322039

License Grant
The parties collaborated to globally develop and commercialize Licensor’s ladiratuzumab vedotin (MK-6440). The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with Keytruda (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors.

Licensor granted Licensee an exclusive license to commercialize Tukysa (tucatinib) for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Licensor will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Licensor will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan.

License Property
Ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors.

Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor to treat a type of breast cancer.

HER2-positive cancers is a protein that can promote the growth of breast cancer cells. Breast cancer cells with high levels of HER2 are called HER2-positive.

Licensor is a biotechnology company that study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from serious diseases including cancer.

Field of Use
The field of use is for the treatment of cancer such as breast cancer.

HER2-positive breast cancer is a type of breast cancer in which breast cancer cells have a protein receptor called HER2 (human epidermal growth factor receptor 2).

Licensee is a premier research-intensive biopharmaceutical company that researches medicines and vaccines to prevent and treat diseases including cancers.

IPSCIO Record ID: 240610

License Grant
For the Research License,  Licensor grants the Licensee of the United Kingdom, a non-exclusive license in the Territory under Licensor Technology as may be specifically designated in writing by  Licensee solely for the purpose of conducting research and development activities on Research Antigens to evaluate Licensees interest in exercising the Options.
License Property
Licensor owns or controls intellectual property rights relating to certain drug conjugation and linker technology.

Antibody-Drug Conjugates (ADCs) are monoclonal antibodies that are linked to potent cell-killing drugs.

Field of Use
The Field means the prevention, treatment, diagnosis or control of all diseases or conditions in humans or animals, for use with certain of Licensees proprietary antigens and antibodies.

ADC technology can be applied to genetically engineered monoclonal antibodies that are chimeric, humanized or fully-human and that bind strongly to and internalize within cancer cells. An important component of ADCs are the conditional linkers that hold and then release the drugs from the monoclonal antibodies. We have a variety of linker technologies including enzyme-cleavable linkers that are very stable in blood.

IPSCIO Record ID: 27461

License Grant
The agreement is to manufacture developmental, clinical and commercial quantities of anti-CD30 monoclonal antibody, which is a component of ADCETRIS. As part of the agreement the Licensor hereby grants an irrevocable, worldwide, nonexclusive license with the right to grant sublicenses, to each Licensor Invention which has been incorporated into the manufacturing process of the Bulk Drug Substance.
License Property
ADCETRIS®, or brentuximab vedotin, is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing the Licensee's proprietary technology.

The treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least one prior multi-agent chemotherapy regimen.

Field of Use
The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.

IPSCIO Record ID: 307594

License Grant
The parties partnered to jointly develop and commercialize three of Licensor’s early-stage investigational bispecific antibody product candidates and enter into a discovery research collaboration for future differentiated antibody therapeutics for cancer.
License Property
Epcoritamab (DuoBody-CD3xCD20) is a bispecific antibody created using Licensor’s proprietary DuoBody technology. Epcoritamab is designed to target CD3, which is expressed on T cells and is part of the T cell receptor signaling complex, and CD20, a clinically well validated therapeutic target. CD20 is expressed on a majority of B cell malignancies, including chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL). In a number of laboratory models, epcoritamab has shown highly effective killing of CD20+ tumors and induced potent tumor cell lysis across a panel of B cell tumor lines. Epcoritamab is currently evaluated in a Phase 1/2 study for multiple hematological B cell malignancies.

The companies will partner to develop Licensor’s next-generation bispecific antibody programs, epcoritamab (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and DuoBody-CD3x5T4. The collaboration combines Licensor’s world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with Licensee’s deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers. Licensor’s DuoBody-CD3 technology engages and directs cytotoxic T cells selectively to tumors to elicit an immune response towards malignant tumor cells. Licensee’s ADC technology allows the delivery of a therapeutic toxin directly to cancer cells while sparing normal, healthy cells, providing for a more targeted, less toxic treatment approach.

Licensor is a biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Licensors technology base consists of validated and proprietary next generation antibody technologies – the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody® platform, which enhances the potential potency of bispecific antibodies through hexamerization.

Field of Use
The field of use is for the treatment of cancer utilizing antibodies. Bispecific antibodies (also known as dual-targeting molecules) bind to two different epitopes, either on the same or on different targets. This may improve the antibodies’ specificity and efficacy in inactivating the disease target cells.

Licensee has a clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers.

IPSCIO Record ID: 266837

License Grant
For the Research License Grants, Licensor shall automatically be deemed to have granted to Licensee a non-exclusive, worldwide license under the Licensor Technology solely to conduct the Research Program.

For the Exclusive License Grants, with respect to the First Exclusive Antigen, and the Option Exercise Fee  with respect to the Second Exclusive Antigen, and commencing as of the date Licensor has received the ADC Access Fee or Option Exercise Fee, as the case may be, from Licensee, Licensor shall automatically be deemed to have granted to Licensee an exclusive, even as to Licensor, license under the Licensor Technology, with the right to sublicense to discover, develop, have developed, make, have made, import, use, offer for sale, and sell Licensed Products that bind specifically to the Exclusive Antigen within the Field in the Territory.

For the Grant of Option, Licensor hereby grants Licensee an option to obtain the Exclusive License of this Agreement to the Second Exclusive Antigen during the Option Period.

For the Replacement Right; Dropped Antigen,  Licensee shall have the right to designate the first exclusive antigen as a Dropped Antigen for purposes of this Agreement by providing Licensor with written notice of same.  Licensee shall have the right to designate one (1) additional Designated Antigen as a replacement for the Dropped Antigen in accordance with  the procedure.

License Property
The patents relate to tumor inhibitors.

The patent applications include Pentapeptide Compounds and uses related thereto; Drug Conjugates and their uses for Treating Cancer, an Autoimmune Disease or an Infectious Disease; and, Monomethylvaline Compound Capable of Conjugation to Ligands.

ADC technology can be widely employed to increase the therapeutic potential of monoclonal antibodies through stable attachment to cell-killing drug payloads.

Field of Use
Field means the treatment and diagnosis of conditions and diseases in humans and animals; provided that with respect to the use of the BMS Technology the Field shall be limited to monoclonal antibody targeting applications.

The proprietary ADC technology for use with Licensee's proprietary antibodies for the treatment of cancer.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.